Medicaid Coverage and Utilization for Novel Therapies for Chronic Rhinosinusitis With Nasal Polyposis

Key Points

• To analyze Medicaid coverage and utilization patterns for novel therapeutic options in chronic rhinosinusitis with nasal polyposis.
• Examined state Medicaid program policies from 2015 to 2024
• Identified preferred drug status for omalizumab and dupilumab
• Analyzed prescription rates among Medicaid patients
• Omalizumab received preferred drug status in 91.4% of state Medicaid programs
• Dupilumab achieved a preferred status in 59.5% of state Medicaid programs
• Omalizumab was the most frequently prescribed therapy among Medicaid patients during the study period